<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risk factors and prevention of peritonitis in peritoneal dialysis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risk factors and prevention of peritonitis in peritoneal dialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Risk factors and prevention of peritonitis in peritoneal dialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John M Burkart, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Peritonitis is a major complication of peritoneal dialysis and a primary reason for patients to switch from peritoneal dialysis to hemodialysis [<a href="#rid1">1</a>]. This topic reviews the causes of peritonitis in this setting and measures to reduce the risk.</p><p>The clinical features and treatment of peritoneal dialysis-associated peritonitis are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis"</a> and  <a class="medical medical_review" href="/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Among patients on peritoneal dialysis, peritonitis is caused by introduction of microbes to the usually sterile peritoneum in the setting of compromised host defenses. Both the introduction of microbes and the compromise of defenses are usually related to the dialysis procedure. We discuss the source of microbial contamination, the possible role of biofilms in preventing eradication of microbes by host defenses, and impairment of macrophages due to the peritoneal dialysis procedure.</p><p class="headingAnchor" id="H1503780060"><span class="h2">Source of infection</span><span class="headingEndMark"> — </span>Sources of peritonitis include intraluminal contamination (or touch contamination during or between exchanges); periluminal contamination (or extension from exit-site or tunnel infection); transvisceral migration from a bowel or, rarely, vaginal leak; and hematogenous dissemination from a remote source, as may occur during dental procedures.</p><p>Peritonitis is most often due to contamination with pathogenic skin bacteria, with <em>Staphylococcus epidermidis</em> and <em>Staphylococcus aureus</em> accounting for the majority of cases [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis"</a>.)</p><p>Contamination with skin bacteria occurs when the patient is performing exchanges or connecting/disconnecting from the transfer set. A patient on continuous ambulatory peritoneal dialysis (CAPD) connects and disconnects from the transfer set at least four times per day and thus 1460 times per year, raising the possibility of an infection even among maximally skilled patients. The near-universal use of "Y" transfer systems has reduced the rate of peritonitis [<a href="#rid3">3</a>]. </p><p>The risk correlates with the number of times the patient has to connect or disconnect. Some studies have suggested an increase in risk with CAPD compared with continuous cycling peritoneal dialysis (CCPD) because of fewer required connections and disconnections.</p><p>Even without contamination during exchanges or disconnects, bacteria can track along the peritoneal catheter and its tunnel. The catheter itself can be a nidus of retained microbes (particularly fungi) that grow directly into the material or under biofilm/slime layers, where they are protected from host defenses. (See <a class="local">'Biofilms'</a> below.)</p><p class="headingAnchor" id="H1327860689"><span class="h2">Biofilms</span><span class="headingEndMark"> — </span>A biofilm is a slimy film of bacteria or fungi that adheres to a surface. Biofilms on the catheter may contribute to relapsing or recurrent infection and to antibiotic resistance, although the clinical significance of biofilms is uncertain [<a href="#rid4">4</a>].</p><p>A large, prospective study demonstrated biofilms in peritoneal catheters removed from patients on peritoneal dialysis; cultures of scrapings from these biofilms were often positive for <em>S. aureus</em> or <em>S. epidermidis</em> [<a href="#rid5">5</a>]. There was, however, no clear relationship to clinical peritonitis [<a href="#rid6">6</a>]. Other studies also showed that biofilms can be present without any evidence of infection [<a href="#rid7">7,8</a>].</p><p>Nevertheless, biofilms may contribute to relapsing or recurrent peritonitis with the same organism [<a href="#rid9">9,10</a>]. In a study including nearly 200 patients who initiated peritoneal dialysis between 1990 and 2000 and had experienced more than one episode of culture-positive peritonitis, approximately 80 percent (157 patients) had at least one repeat infection with the same organism [<a href="#rid10">10</a>]. More than 50 percent of the peritonitis episodes among 124 patients were caused by the same organism, and 59 of 90 patients (65 percent) of those with more than four infectious episodes had at least one-half or more of their episodes caused by the same organism.</p><p>Another report found that patients with multiple episodes of peritonitis were likely to have stable biofilms, positive biofilm cultures, and a high incidence of catheter loss [<a href="#rid9">9</a>]. Troublesome organisms that notoriously form biofilms in this setting are staphylococci and <em>Pseudomonas</em> [<a href="#rid11">11</a>]. Intraperitoneal urokinase has been suggested as a treatment of biofilm as a potential cause of relapsing infection [<a href="#rid12">12,13</a>].</p><p class="headingAnchor" id="H2936547857"><span class="h2">Compromised host defenses</span><span class="headingEndMark"> — </span>An intact peritoneum and the defense mechanisms of the mesothelium are important barriers to the development of peritonitis in patients on peritoneal dialysis. However, these host defenses are compromised by the peritoneal dialysis procedure:</p><p class="bulletIndent1"><span class="glyph">●</span>The continuous presence of a large amount of fluid in the peritoneal cavity can impair host defenses. Mesothelial surfaces have extraordinary host defense mechanisms when the surfaces are allowed close proximity to each other [<a href="#rid14">14</a>]. The presence of dialysis solution prevents close proximity of mesothelial surfaces and also dilutes macrophage and cytokine levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The composition of the peritoneal dialysis fluid may promote microbial growth and inhibit host defense. Standard dialysis fluids have a high glucose concentration, which promotes microbial growth. The high glucose concentration, the low pH, and glucose degradation products (GDPs) may also alter host response. Newer peritoneal dialysis fluids that contain glucose polymers (such as <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a>), amino acids rather than glucose, or fluids that results in fewer GDPs may be relatively less harmful to neutrophil and macrophage function, although this has not been proven. (See  <a class="medical medical_review" href="/d/html/1905.html" rel="external">"Peritoneal dialysis solutions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resident macrophages and cytokines that potentially prevent infection are constantly removed during each exchange of dialysis fluids.</p><p></p><p>As a result of factors that are specific to patients on peritoneal dialysis, a relatively small inoculum of bacteria, as often occurs with a touch contamination, can readily induce peritonitis in a patient on peritoneal dialysis; in contrast, a similar inoculation during surgical laparotomy seldom causes peritonitis [<a href="#rid14">14,15</a>].</p><p class="headingAnchor" id="H3929213392"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H4260539172"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>The reported incidence of peritonitis ranges widely [<a href="#rid16">16-21</a>]. A retrospective study of 1677 patients on incident peritoneal dialysis revealed a first-year peritonitis rate of 42 per 100 patient-years [<a href="#rid20">20</a>]. Of 463 first peritonitis cases, 336 (72.6 percent) occurred within the first six months of peritoneal dialysis.</p><p class="headingAnchor" id="H3967669717"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Important modifiable risk factors include recent invasive intervention (colonoscopy, sigmoidoscopy, cystoscopy, hysteroscopy) or dental procedures, nasal <em>S. aureus</em> carriage, and exit-site and/or tunnel infections [<a href="#rid22">22-25</a>]. (See <a class="local">'Prophylactic treatment with procedures'</a> below.)</p><p>Other factors that have been associated in various studies include constipation, smoking and chronic obstructive pulmonary disease (COPD), domestic pets, obesity, depression, hypokalemia, hypoalbuminemia, prior hemodialysis, use of bioincompatible solutions, and living far away from the peritoneal dialysis clinic [<a href="#rid26">26-29</a>].</p><p>Selected risk factors are discussed below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Invasive interventions </strong>– Invasive interventions (colonoscopy, sigmoidoscopy, cystoscopy, hysteroscopy) or dental procedures are risk factors for peritonitis [<a href="#rid22">22-25,30-33</a>]. In one study of 79 continuous ambulatory peritoneal dialysis (CAPD) patients undergoing colonoscopies without prophylactic antibiotics, the risk of peritonitis was 6.2 percent [<a href="#rid23">23</a>]. Similar results were observed in another study of patients on peritoneal dialysis undergoing 99 endoscopies [<a href="#rid30">30</a>]. In this study, peritonitis only occurred following invasive procedures such as biopsy, polypectomy, or intrauterine device (IUD) implantation but not following endoscopy without an additional procedure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>S. aureus </em></strong><strong>nasal carriage </strong>– The primary reservoir for <em>S. aureus</em> is the anterior nares [<a href="#rid34">34</a>]. Nasal carriers of <em>S. aureus</em> are at increased risk to develop <em>S. aureus</em> exit-site infections, tunnel infections, and, possibly, peritonitis [<a href="#rid35">35-37</a>]. One landmark report found that nasal carriers were four times more likely to develop exit-site infections than noncarriers; the overall peritonitis rates were not different between the groups, but all cases of <em>S. aureus</em> peritonitis occurred in the carriers [<a href="#rid35">35</a>]. Exit-site infections are a known risk factor for peritonitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exit-site infection </strong>– Catheter exit-site infections are associated with increased risk of peritonitis [<a href="#rid38">38-40</a>]. A secondary analysis of a randomized trial compared two antimicrobial ointments among 203 stable patients on peritoneal dialysis [<a href="#rid39">39</a>]. Over 18 months, there were 44 exit-site infections and 87 peritonitis episodes. Patients who had an exit-site infection were much more likely to develop peritonitis within 30 days, even if the exit-site infection was appropriately treated. The risk of peritonitis decreased over time, with hazard ratios of 11.1, 5.3, and 4.9 at 15, 45, and 60 days, respectively. Surprisingly, in this study, the organisms that caused peritonitis were most often unrelated to those that caused the exit-site infection, suggesting that the mechanism of increased susceptibility to peritonitis is not straightforward. However, this observation needs to be confirmed in a larger study. Regardless of the mechanism by which exit-site infections lead to peritonitis, these data support the need for aggressive prevention and treatment of exit-site infections [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/1888.html" rel="external">"Peritoneal catheter exit-site and tunnel infections in peritoneal dialysis in adults", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Break in technique </strong>– Obvious breaks in technique (such as when and where the open end or unsecured end of the catheter touches a nonsterile object [eg, ungloved hands, table outside sterile field, patient's skin, etc]) are associated with increased risk of infection [<a href="#rid42">42,43</a>]. Breaks in technique may be more likely shortly after patients switch from one peritoneal dialysis modality to another (eg, switching from CAPD to continuous cycling peritoneal dialysis [CCPD]) or change dialysis product vendors, when patients may perform connection procedures that are inappropriate for their new equipment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Underlying gastrointestinal pathology </strong>–<strong> </strong>Peritonitis can be induced by underlying pathology of the gastrointestinal tract, resulting in significant morbidity and mortality [<a href="#rid44">44,45</a>]. These conditions include cholecystitis, appendicitis, ruptured diverticulum, and perforation during endoscopy [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Constipation </strong>– Chronic constipation and the acute treatment of constipation increase the risk of peritonitis [<a href="#rid46">46-49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors of uncertain significance</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Continuous ambulatory peritoneal dialysis </strong>– Some [<a href="#rid50">50-53</a>], but not all [<a href="#rid16">16,54,55</a>], studies have suggested that the rate of peritonitis is higher with CAPD compared with CCPD. This is presumed to be due to fewer required connections and disconnections. However, with the use of contemporary systems, the selected modality likely has little clinical impact on an individual patient's peritonitis risk [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Use of nonbiocompatible dialysate </strong>– As noted above, repeated instillation of peritoneal dialysis fluids may alter host defense (see <a class="local">'Compromised host defenses'</a> above). More biocompatible fluids theoretically could reduce the risk of peritonitis. However, the data are inconclusive and do not support the use of biocompatible dialysate solely to prevent peritonitis. (See <a class="local">'Modality and choice of dialysate'</a> below.)</p><p></p><p class="bulletIndent2">Randomized clinical trials as well as observation studies have come to different conclusions regarding the efficacy of biocompatible fluids [<a href="#rid57">57-62</a>]. While one trial (BALANZ) of 183 patients found that biocompatible fluids were associated with a reduced rate of peritonitis (0.3 versus 0.49 episodes per patient-year) [<a href="#rid57">57</a>], two previous trials (267 and 50 patients, respectively) did not find a difference in peritonitis rates in patients receiving biocompatible fluid [<a href="#rid61">61,62</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypokalemia</strong> – Hypokalemia may be a risk factor for peritonitis [<a href="#rid63">63-65</a>], possibly by reducing gut motility. In an open-label, 52-week, randomized trial of 167 patients on peritoneal dialysis who had a history of hypokalemia, <a class="drug drug_general" data-topicid="9795" href="/d/drug information/9795.html" rel="external">potassium chloride</a> administration based on a protocol to maintain serum potassium levels between 4 and 5 mEq/L resulted in fewer patients developing peritonitis than potassium chloride administration based on physician judgement when serum potassium levels were less than 3.5 mEq/L (13 versus 24 patients) [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastric acid suppression</strong> – The use of gastric acid suppressants (ie, histamine 2 receptor antagonists [H2RAs] and proton pump inhibitors [PPIs]) may be a risk factor for peritonitis [<a href="#rid67">67-69</a>]. In a meta-analysis of six observational studies that included 829 patients on peritoneal dialysis, H2RA use was associated with a higher risk of enteric peritonitis (odds ratio 1.40; 95% CI 1.01–1.93) [<a href="#rid70">70</a>]. Some observational data suggest that the risk of peritonitis may be greater with H2RAs than with PPIs [<a href="#rid67">67,69</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>It is important to prevent peritonitis. Peritonitis often results in morbidity, transfer to hemodialysis, and, occasionally, death [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis", section on 'Prognosis'</a>.)</p><p>We agree with the International Society of Peritoneal Dialysis (ISPD) guidelines that all peritoneal dialysis programs should monitor peritonitis-related events (in episodes/patient year at risk) as part of a Continuous Quality Improvement (CQI) program [<a href="#rid22">22</a>]. The ISPD guidelines have cited a target overall rate of ≤0.5 episodes/year at risk [<a href="#rid22">22</a>]. A rate higher than this, or detection of trends where overall rates are increasing, should provoke a review of training practices and clinical practices [<a href="#rid22">22</a>].</p><p>Preventive measures are discussed below. Our approach is largely consistent with the ISPD guidelines [<a href="#rid22">22</a>].</p><p>Considerations prior to placement of the peritoneal dialysis catheter (including catheter design with respect to body habitus) are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1885.html" rel="external">"Placement of the peritoneal dialysis catheter"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Proper training and home visits</span><span class="headingEndMark"> — </span>All patients must be trained in aseptic techniques and instructed in the definition of and proper response to contamination [<a href="#rid72">72,73</a>]. Training should be conducted by nursing staff with appropriate qualification and training [<a href="#rid74">74</a>].</p><p>After the initial training, patients should be monitored and various steps of the peritoneal dialysis therapy reviewed from time to time to be sure that patients are following the protocol correctly. Brief retraining should be considered after any episode of peritonitis.</p><p>The benefits of training as well as retraining were reported in a study of new patients who were randomly assigned to either standard or enhanced training (adult learning) [<a href="#rid75">75</a>]. At two years, enhanced training was associated with significantly fewer exit-site infections, as well as a trend toward a decreased peritonitis rate.</p><p>Ongoing education is also essential for nurses providing patient training. In a single-center, observational study, there was a negative association between trainers' length of time in practice and incidence of gram-positive peritonitis among incident patients [<a href="#rid76">76</a>].</p><p>Home visits by the peritoneal dialysis nursing staff may be helpful to identify and avoid potential problems. The location within the home where exchanges take place, the presence of pets, and the overall cleanliness of the home environment are a few of the factors to review in infection prevention [<a href="#rid77">77</a>].</p><p>Special attention is needed in cases when patients transition from one device to another (such as a newer model of the current manufacturer or a device from a different manufacturer). In these situations, the sequence of steps or actual steps for the disconnect or connect procedure may be different. In addition, patients may revert to previously learned techniques or habits (therapeutic drift), thereby increasing the risk of contamination or malfunction of the new device. Thus, during training, the staff will need to anticipate any old habits that could accidentally be used with the new device. New policies and procedures should be developed to preemptively address these issues for consistent training of patients who are in transition to new devices.</p><p>We ask patients to remove faucet aerators from their homes in order to minimize the risk of <em>Pseudomonas</em> peritonitis. <em>Pseudomonas</em> bacteria commonly colonize aerators used on faucets [<a href="#rid78">78</a>]. However, studies have not demonstrated that this practice reduces the risk of peritonitis.</p><p>Monitoring for depression should be part of routine assessment. Depression has been associated with increased risk of peritonitis. (See <a class="local">'Risk factors'</a> above.)</p><p class="headingAnchor" id="H142398712"><span class="h2">Transfer set</span><span class="headingEndMark"> — </span>For all patients, we recommend the use of a "disconnect" or "Y" system rather than a spike system. Multiple reports have demonstrated a reduction in peritonitis risk with single-use disconnect systems [<a href="#rid3">3,79-85</a>]. This was best shown in a systematic review of seven trials consisting of 485 patients in which the use of the disconnect set, compared with the standard spike system, was associated with a lower risk of peritonitis (relative risk [RR] 0.64, 95% CI 0.53-0.77) [<a href="#rid3">3</a>]; a similar benefit with the disconnect system in terms of the peritonitis rate (RR 0.49, 95% CI 0.40-0.61) was reported upon analysis of eight trials and 7417 patient-months.</p><p>Disconnect systems include a standard Y system and a double-bag Y system in which both dialysis solutions and drain bags are preattached.</p><p>If available, we suggest the use of disconnect systems with double-bag systems [<a href="#rid86">86</a>]. Some [<a href="#rid54">54,73,85,87-92</a>], though not all [<a href="#rid87">87</a>], studies suggest that, compared with standard Y systems, double-bag systems may be associated with lower peritonitis rates since they more effectively flush out possible contamination during attachment  (<a class="graphic graphic_figure graphicRef64131" href="/d/graphic/64131.html" rel="external">figure 1</a>) [<a href="#rid54">54,73,85,87-92</a>]. In a study of 147 patients who were randomly assigned to a double-bag system, a disconnect Y set without attached double bag, or a conventional straight transfer system, the average peritonitis-free interval was highest in the twin-bag system group (24.8 months versus 12 and 6.1 months for the standard Y-set and straight transfer system groups, respectively) [<a href="#rid91">91</a>].</p><p>However, a systematic review of randomized, prospective studies found no statistically significant difference with double-bag and Y systems concerning peritonitis rates (RR 0.90, 95% CI 0.49-1.66) and exit-site/tunnel infection rates (RR 1.04, 95% CI 0.52-2.06) [<a href="#rid3">3</a>]. Despite this, there was a trend in favor of double-bag systems for experiencing peritonitis episodes (RR 0.59, 95% CI 0.35-1.01), which was based upon data from three trials consisting of 292 patients [<a href="#rid87">87,88,91</a>]. There is limited evidence that different double-bag systems may not be associated with the same peritonitis rates [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H2578380625"><span class="h2">Modality and choice of dialysate</span><span class="headingEndMark"> — </span>We do not choose the peritoneal dialysis modality based on risk of peritonitis. With the use of contemporary connection systems, the modality likely has little clinical impact on an individual patient's peritonitis risk, and many individual patient variables inform the choice of modality [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/d/html/1858.html" rel="external">"Evaluating patients for chronic peritoneal dialysis and selection of modality"</a>.)</p><p>We do not select peritoneal dialysis solution on the basis of peritonitis risk. As noted above, biocompatible fluids could reduce the risk of peritonitis. (See <a class="local">'Risk factors'</a> above.)</p><p>However, randomized clinical trials as well as observation studies have come to different conclusions regarding the efficacy of biocompatible fluids [<a href="#rid57">57-62</a>]. While one trial (BALANZ) of 183 patients found that biocompatible fluids were associated with a reduced rate of peritonitis (0.3 versus 0.49 episodes per patient-year) [<a href="#rid57">57</a>], two previous trials (267 and 50 patients respectively) did not find a difference in peritonitis rates in patients receiving biocompatible fluid [<a href="#rid61">61,62</a>].</p><p>There are insufficient data to inform the choice of peritoneal dialysis solution based on a peritonitis risk reduction strategy.</p><p class="headingAnchor" id="H923071133"><span class="h2">Approach after breaks in technique</span><span class="headingEndMark"> — </span>We change the transfer set after all recognized break in technique. We give antibiotics in selected cases depending on the risk of infection:</p><p class="bulletIndent1"><span class="glyph">●</span>If the contamination occurred distal to a closed transfer set clamp but the tubing and dialysate bag are not leaking (referred to as a "dry contamination"), we just change the transfer set. We do not give antibiotics, because, in our experience, the risk of resulting infection is relatively low.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there was a leak in the dialysate bags, or a break in tubing distal to an open clamp, but fluid was not being infused, we change the transfer set, and we give three days of oral <a class="drug drug_general" data-topicid="9231" href="/d/drug information/9231.html" rel="external">cephalexin</a> (500 mg twice daily). If the patient is allergic to cephalosporins, we give <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> 500 mg daily for three days. Some clinicians use one dose of intraperitoneal antibiotics instead.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there was a leak in tubing proximal to a closed clamp or if contamination occurred while peritoneal fluid was being infused, we change the transfer set and we give one dose of intraperitoneal antibiotics. This type of contamination is associated with the highest risk of infection. We generally use intraperitoneal <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a> for prophylaxis in this setting, but for patients colonized with methicillin-resistant staphylococcus aureus (MRSA) or at high risk of MRSA, intraperitoneal <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> plus an additional intraperitoneal antibiotic such as <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>, <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, or an aminoglycoside is a reasonable alternative  (<a class="graphic graphic_table graphicRef60452" href="/d/graphic/60452.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef79841" href="/d/graphic/79841.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/4043.html" rel="external">"Antimicrobial prophylaxis for prevention of surgical site infection in adults", section on 'Role of vancomycin'</a>.) </p><p></p><p class="headingAnchor" id="H8"><span class="h2">Prophylactic treatment with procedures</span><span class="headingEndMark"> — </span>Our standard practice prior to procedures is described below. However, there has been no systematic evaluation of efficacy, and approaches vary [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H646170429"><span class="h3">All procedures</span><span class="headingEndMark"> — </span>For patients on peritoneal dialysis undergoing surgery or invasive procedures involving the abdomen or pelvis, including minimally invasive gastrointestinal, gynecologic, and urologic procedures, we suggest first draining the peritoneal fluid. We also drain the dialysate fluid before dental procedures. The presence of peritoneal dialysis fluid may promote bacterial growth and dilute concentrations of native host defense mechanisms. (See <a class="local">'Source of infection'</a> above and  <a class="medical medical_review" href="/d/html/139769.html" rel="external">"Issues in patients on peritoneal dialysis undergoing surgery", section on 'Draining the abdomen before surgery'</a>.)</p><p>We give antibiotics prior to selected procedures. Specific regimens are described below. (See <a class="local">'Colonoscopy and upper endoscopy'</a> below and <a class="local">'Gynecologic procedures'</a> below and <a class="local">'Dental procedures'</a> below.)</p><p class="headingAnchor" id="H2879197816"><span class="h3">Colonoscopy and upper endoscopy</span><span class="headingEndMark"> — </span>Dialysate fluid is drained the day of the procedure, and the abdomen is kept dry (see <a class="local">'All procedures'</a> above). We keep the abdomen dry until the day following the procedure (ie, the first day after the procedure) unless a biopsy or polypectomy is performed. For patients who undergo biopsy or polypectomy, we aim to keep the abdomen dry for longer periods; optimally, we restart peritoneal dialysis on the third day after the procedure unless dialysis is needed sooner.</p><p>We give prophylactic antibiotics prior to colonoscopy and upper endoscopy. Other experts, however, only give prophylactic antibiotics before colonoscopy (but not upper endoscopy), since evidence supporting such treatment before upper endoscopy is lacking. We administer a single intraperitoneal dose of <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> 160 mg in the overnight dwell or in cycler bags one night prior to the procedure, in addition to prescribing oral <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> 500 mg to be taken four times daily for three days (starting the day prior to the procedure) [<a href="#rid94">94</a>]. However, some clinicians only use oral antibiotics [<a href="#rid95">95</a>].</p><p>Prophylactic antibiotics decrease the risk of peritonitis following colonoscopy [<a href="#rid23">23,30,95</a>]. In one study of 77 continuous ambulatory peritoneal dialysis (CAPD) patients who underwent 97 colonoscopies, no cases of peritonitis were diagnosed in 18 patients who received prophylactic antibiotics, but five cases were diagnosed among 79 patients who did not [<a href="#rid23">23</a>]. </p><p class="headingAnchor" id="H3060425257"><span class="h3">Gynecologic procedures</span><span class="headingEndMark"> — </span>We drain the dialysate fluid prior to gynecologic procedures, including hysteroscopy, placement of intrauterine device (IUD), cervical biopsy, and routine gynecologic exams (ie, pelvic exam and Papanicolaou [Pap] test). Our approach to restarting peritoneal dialysis after gynecologic procedures varies according to whether a biopsy or polypectomy is performed and is the same as for patients undergoing colonoscopy and endoscopy. (See <a class="local">'Colonoscopy and upper endoscopy'</a> above.)</p><p>For hysteroscopy, placement of IUD, and cervical biopsy, we also give prophylactic antibiotics. The antibiotics are the same as those administered prior to colonoscopy and endoscopy (see <a class="local">'Colonoscopy and upper endoscopy'</a> above). We generally do not give prophylactic antibiotics for routine gynecologic exams (ie, pelvic exam and Pap test without cervical biopsy or IUD placement). However, some clinicians give oral antibiotics for such exams.</p><p>Prophylactic antibiotics decrease the risk of peritonitis following gynecologic procedures [<a href="#rid23">23,30,96</a>]. In a study of 45 patients on peritoneal dialysis who underwent 125 endoscopies including hysteroscopy, peritonitis occurred in patients who were not treated with antibiotics but not in those who were [<a href="#rid30">30</a>]. All episodes of peritonitis occurred following endoscopy with invasive procedures (including biopsy, polypectomy, or IUD implantation).</p><p class="headingAnchor" id="H2395306778"><span class="h3">Dental procedures</span><span class="headingEndMark"> — </span>We drain the dialysate fluid prior to dental procedures and restart peritoneal dialysis the day after the procedure.</p><p>We give oral antibiotics prior to invasive or potentially invasive dental procedures, including routine dental cleanings. Dental procedures are associated with a high risk of bacteremia and have been associated with peritonitis among patients on peritoneal dialysis [<a href="#rid97">97</a>]. We give 2 grams of <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> orally two hours prior to the procedure.</p><p class="headingAnchor" id="H3429215339"><span class="h2">Prophylactic antibiotics for catheter exit-site leaks</span><span class="headingEndMark"> — </span>For patients with peritoneal catheter exit-site leaks, we suggest prophylactic antibiotic therapy. Because patients with exit-site leaks are at risk of developing peritonitis [<a href="#rid98">98</a>], we typically administer antibiotics for the duration of the leak. We generally use intraperitoneal <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a> for prophylaxis in this setting, but for patients colonized with MRSA or at high risk of MRSA, intraperitoneal <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> plus an additional intraperitoneal antibiotic such as <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>, <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, or an aminoglycoside is a reasonable alternative  (<a class="graphic graphic_table graphicRef60452" href="/d/graphic/60452.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef79841" href="/d/graphic/79841.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/4043.html" rel="external">"Antimicrobial prophylaxis for prevention of surgical site infection in adults", section on 'Role of vancomycin'</a>.)</p><p>Our overall approach to the management of pericatheter leaks is detailed elsewhere. (See  <a class="medical medical_review" href="/d/html/1883.html" rel="external">"Noninfectious complications of peritoneal dialysis catheters", section on 'Pericatheter leakage'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Prevention and treatment of catheter infections</span><span class="headingEndMark"> — </span>We use measures to prevent and treat exit-site and tunnel infections. (See  <a class="medical medical_review" href="/d/html/1888.html" rel="external">"Peritoneal catheter exit-site and tunnel infections in peritoneal dialysis in adults", section on 'Prevention'</a> and  <a class="medical medical_review" href="/d/html/1888.html" rel="external">"Peritoneal catheter exit-site and tunnel infections in peritoneal dialysis in adults", section on 'Treatment'</a>.)</p><p>Exit-site and tunnel infections are important risk factor for peritonitis, particularly for infections caused by <em>S. aureus</em> and <em>Pseudomonas aeruginosa</em>.</p><p>Prevention of exit-site infections and prompt treatment of any exit-site infection are logical steps in prevention of peritonitis [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H2475084598"><span class="h2">Antifungal prophylaxis during antibiotic therapy</span><span class="headingEndMark"> — </span>Treatment with systemic antibiotics is a major risk factor for the development of fungal peritonitis among patients on peritoneal dialysis. Antifungal prophylaxis during the course of antibiotic therapy may reduce the risk of subsequent fungal peritonitis. Our approach to antifungal prophylaxis in this setting is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1982.html" rel="external">"Fungal peritonitis in peritoneal dialysis"</a> and  <a class="medical medical_review" href="/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis", section on 'Role of antifungal prophylaxis'</a>.)</p><p class="headingAnchor" id="H17195922"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/4426.html" rel="external">"Patient education: Peritoneal dialysis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Among patients on peritoneal dialysis, peritonitis is most often due to contamination with pathogenic skin bacteria, with <em>Staphylococcus epidermidis</em> and <em>Staphylococcus aureus</em> accounting for the majority of cases. Contamination with skin bacteria occurs when the patient is performing exchanges or connecting/disconnecting from the transfer set. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Important modifiable risk factors include recent invasive intervention (colonoscopy, sigmoidoscopy, cystoscopy, hysteroscopy) or dental procedures, nasal <em>S. aureus</em> carriage, and exit-site and/or tunnel infections. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong>– Our approach to the prevention of peritonitis is consistent with the International Society of Peritoneal Dialysis (ISPD) guidelines. In addition to careful training of patients, we use the following measures in all patients on peritoneal dialysis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preferred transfer set</strong> – We recommend a single-use "disconnect" or "Y" system rather than the older spike system (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Multiple reports have demonstrated a reduction in peritonitis risk with single-use disconnect systems.</p><p></p><p class="bulletIndent2">We also suggest the use of disconnect systems with double-bag systems rather than standard Y system (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Some studies suggest that, compared with standard Y systems, double-bag systems may be associated with lower peritonitis rates. (See <a class="local">'Transfer set'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of breaks in technique</strong> – Following all breaks in technique, we change the transfer set. For patients with a leak in the dialysate bags or break in tubing in the setting of an open transfer set clamp, or proximal to a closed transfer set clamp, we suggest giving antibiotics (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This type of contamination is associated with a high risk of infection. Our approach to antibiotic administration is as follows (see <a class="local">'Approach after breaks in technique'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with a leak in the dialysate bags, or a break in tubing distal to an open clamp, providing fluid is not being infused, we give oral <a class="drug drug_general" data-topicid="9231" href="/d/drug information/9231.html" rel="external">cephalexin</a> (500 mg twice daily).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who have a leak in tubing proximal to a closed clamp or if contamination occurred while peritoneal fluid was being infused, we give one dose of intraperitoneal antibiotics. We generally use intraperitoneal <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a> for prophylaxis in this setting, but for patients colonized with methicillin-resistant staphylococcus aureus (MRSA) or at high risk of MRSA, intraperitoneal <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> plus an additional intraperitoneal antibiotic such as <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>, <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, or an aminoglycoside is a reasonable alternative  (<a class="graphic graphic_table graphicRef60452" href="/d/graphic/60452.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef79841" href="/d/graphic/79841.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Draining the abdomen</strong> – For patients on peritoneal dialysis undergoing surgery or invasive procedures involving the abdomen or pelvis, including minimally invasive gastrointestinal, gynecologic, and urologic procedures, we suggest first draining the peritoneal fluid (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We also drain the dialysate fluid before dental procedures. The presence of peritoneal dialysis fluid may promote bacterial growth and dilute concentrations of native host defense mechanisms (see <a class="local">'All procedures'</a> above). The preferred duration of a dry abdomen after colonoscopy, upper endoscopy, and gynecologic procedures varies according to whether a biopsy or polypectomy is performed. (See <a class="local">'Colonoscopy and upper endoscopy'</a> above and <a class="local">'Gynecologic procedures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Use of prophylactic antibiotics</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Colonoscopy and invasive gynecologic procedures</strong> – For patients on peritoneal dialysis undergoing colonoscopy or invasive gynecologic procedures, we suggest prophylactic antibiotics (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Although we also give prophylactic antibiotics prior to upper endoscopy, other experts do not. We administer a single intraperitoneal dose of <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> 160 mg in the overnight dwell or in cycler bags one night prior to the procedure, in addition to prescribing oral <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> 500 mg to be taken four times daily for three days (starting the day prior to the procedure). (See <a class="local">'Colonoscopy and upper endoscopy'</a> above and <a class="local">'Gynecologic procedures'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dental procedures</strong> – For patients on peritoneal dialysis undergoing invasive dental procedures, we suggest prophylactic antibiotics (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Dental procedures are associated with a high risk of bacteremia and have been associated with peritonitis among patients on peritoneal dialysis. A preferred regimen is a single oral dose of <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> (2 grams) given two hours prior to dental procedures. (See <a class="local">'Dental procedures'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Catheter exit-site leaks</strong> – For patients with peritoneal catheter exit-site leaks, we suggest prophylactic antibiotic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Because patients with exit-site leaks are at risk of developing peritonitis, we typically administer antibiotics for the duration of the leak. (See <a class="local">'Prophylactic antibiotics for catheter exit-site leaks'</a> above.) </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Voinescu CG, Khanna R. Peritonitis in peritoneal dialysis. Int J Artif Organs 2002; 25:249.</a></li><li><a class="nounderline abstract_t">Szeto CC, Chow KM, Wong TY, et al. Influence of climate on the incidence of peritoneal dialysis-related peritonitis. Perit Dial Int 2003; 23:580.</a></li><li><a class="nounderline abstract_t">Strippoli GF, Tong A, Johnson D, et al. Catheter-related interventions to prevent peritonitis in peritoneal dialysis: a systematic review of randomized, controlled trials. J Am Soc Nephrol 2004; 15:2735.</a></li><li><a class="nounderline abstract_t">Anwar H, Dasgupta MK, Costerton JW. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother 1990; 34:2043.</a></li><li class="breakAll">Dasgupta MK, Ulan RA, Bettcher KB, et al. Effects of exit site infection and peritonitis on the distribution of biofilm-encased adherent bactereial microcolonies (BABM) on Tenchkhoff (T) catheters in patients undergoing continuous ambulatory. In: Advances in Continuous Ambulatory Peritoneal Dialysis, Khanna R, Nolph KD, Prowand BF, et al (Eds), Univesrity of Toronto Press, Toronto 1986. p.102.</li><li><a class="nounderline abstract_t">Dasgupta MK, Bettcher KB, Ulan RA, et al. Relationship of adherent bacterial biofilms to peritonitis in chronic ambulatory peritoneal dialysis. Perit Dial Bull 1987; 7:168.</a></li><li><a class="nounderline abstract_t">Verger C, Chesneau AM, Thibault M, et al. Biofilm on the Tenckhoff catheter: A negligible source of contamination. Perit Dial Bull 1987; 7:178.</a></li><li><a class="nounderline abstract_t">Swartz R, Messana J, Holmes C, Williams J. Biofilm formation on peritoneal catheters does not require the presence of infection. ASAIO Trans 1991; 37:626.</a></li><li><a class="nounderline abstract_t">Dasgupta MK, Kowalewaska-Grochowska K, Costerton JW. Biofilm and peritonitis in peritoneal dialysis. Perit Dial Int 1993; 13 Suppl 2:S322.</a></li><li><a class="nounderline abstract_t">Finkelstein ES, Jekel J, Troidle L, et al. Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. Am J Kidney Dis 2002; 39:1278.</a></li><li><a class="nounderline abstract_t">Reid G, Khoury AE, Preston CA, Costerton JW. Influence of dextrose dialysis solutions on adhesion of Staphylococcus aureus and Pseudomonas aeruginosa to three catheter surfaces. Am J Nephrol 1994; 14:37.</a></li><li><a class="nounderline abstract_t">Demoulin N, Goffin E. Intraperitoneal urokinase and oral rifampicin for persisting asymptomatic dialysate infection following acute coagulase-negative staphylococcus peritonitis. Perit Dial Int 2009; 29:548.</a></li><li><a class="nounderline abstract_t">Tong MK, Leung KT, Siu YP, et al. Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis. J Nephrol 2005; 18:204.</a></li><li><a class="nounderline abstract_t">Brulez HF, Verbrugh HA. First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Perit Dial Int 1995; 15:S24.</a></li><li><a class="nounderline abstract_t">Williams JD. Biocompatibility in peritoneal dialysis: definitions and mechanisms. Perit Dial Int 1995; 15:S5.</a></li><li><a class="nounderline abstract_t">Oo TN, Roberts TL, Collins AJ. A comparison of peritonitis rates from the United States Renal Data System database: CAPD versus continuous cycling peritoneal dialysis patients. Am J Kidney Dis 2005; 45:372.</a></li><li><a class="nounderline abstract_t">Cnossen TT, Usvyat L, Kotanko P, et al. Comparison of outcomes on continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis: results from a USA database. Perit Dial Int 2011; 31:679.</a></li><li><a class="nounderline abstract_t">Brown MC, Simpson K, Kerssens JJ, et al. Peritoneal dialysis-associated peritonitis rates and outcomes in a national cohort are not improving in the post-millennium (2000-2007). Perit Dial Int 2011; 31:639.</a></li><li><a class="nounderline abstract_t">McQuillan RF, Chiu E, Nessim S, et al. A randomized controlled trial comparing mupirocin and polysporin triple ointments in peritoneal dialysis patients: the MP3 Study. Clin J Am Soc Nephrol 2012; 7:297.</a></li><li><a class="nounderline abstract_t">Pulliam J, Li NC, Maddux F, et al. First-year outcomes of incident peritoneal dialysis patients in the United States. Am J Kidney Dis 2014; 64:761.</a></li><li><a class="nounderline abstract_t">Piraino B, Bernardini J, Brown E, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int 2011; 31:614.</a></li><li><a class="nounderline abstract_t">Li PK, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 2022; 42:110.</a></li><li><a class="nounderline abstract_t">Yip T, Tse KC, Lam MF, et al. Risks and outcomes of peritonitis after flexible colonoscopy in CAPD patients. Perit Dial Int 2007; 27:560.</a></li><li><a class="nounderline abstract_t">Poortvliet W, Selten HP, Raasveld MH, Klemt-Kropp M. CAPD peritonitis after colonoscopy: follow the guidelines. Neth J Med 2010; 68:377.</a></li><li><a class="nounderline abstract_t">Machuca E, Ortiz AM, Rabagliati R. Streptococcus viridans-associated peritonitis after gastroscopy. Adv Perit Dial 2005; 21:60.</a></li><li><a class="nounderline abstract_t">Cho Y, Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J Kidney Dis 2014; 64:278.</a></li><li><a class="nounderline abstract_t">Prasad N, Gupta A, Sharma RK, et al. Impact of nutritional status on peritonitis in CAPD patients. Perit Dial Int 2007; 27:42.</a></li><li><a class="nounderline abstract_t">Wang Q, Bernardini J, Piraino B, Fried L. Albumin at the start of peritoneal dialysis predicts the development of peritonitis. Am J Kidney Dis 2003; 41:664.</a></li><li><a class="nounderline abstract_t">Troidle L, Watnick S, Wuerth DB, et al. Depression and its association with peritonitis in long-term peritoneal dialysis patients. Am J Kidney Dis 2003; 42:350.</a></li><li><a class="nounderline abstract_t">Wu HH, Li IJ, Weng CH, et al. Prophylactic antibiotics for endoscopy-associated peritonitis in peritoneal dialysis patients. PLoS One 2013; 8:e71532.</a></li><li><a class="nounderline abstract_t">Li PK, Leung CB, Leung AK, et al. Posthysteroscopy fungal peritonitis in a patient on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993; 21:446.</a></li><li><a class="nounderline abstract_t">Fried L, Bernardini J, Piraino B. Iatrogenic peritonitis: the need for prophylaxis. Perit Dial Int 2000; 20:343.</a></li><li><a class="nounderline abstract_t">Au CWH, Chan CK, Wong CK, et al. Clinical characteristics and outcomes of peritoneal dialysis (PD)-related peritonitis after colonoscopy. Perit Dial Int 2023; 43:475.</a></li><li><a class="nounderline abstract_t">WHITE A, SMITH J. NASAL RESERVOIR AS THE SOURCE OF EXTRANASAL STAPHYLOCOCCI. Antimicrob Agents Chemother (Bethesda) 1963; 161:679.</a></li><li><a class="nounderline abstract_t">Luzar MA, Coles GA, Faller B, et al. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990; 322:505.</a></li><li><a class="nounderline abstract_t">Nouwen J, Schouten J, Schneebergen P, et al. Staphylococcus aureus carriage patterns and the risk of infections associated with continuous peritoneal dialysis. J Clin Microbiol 2006; 44:2233.</a></li><li><a class="nounderline abstract_t">Lye WC, Leong SO, van der Straaten J, Lee EJ. Staphylococcus aureus CAPD-related infections are associated with nasal carriage. Adv Perit Dial 1994; 10:163.</a></li><li><a class="nounderline abstract_t">Gupta B, Bernardini J, Piraino B. Peritonitis associated with exit site and tunnel infections. Am J Kidney Dis 1996; 28:415.</a></li><li><a class="nounderline abstract_t">van Diepen AT, Tomlinson GA, Jassal SV. The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients. Clin J Am Soc Nephrol 2012; 7:1266.</a></li><li><a class="nounderline abstract_t">Szeto CC, Chow KM, Kwan BC, et al. Staphylococcus aureus peritonitis complicates peritoneal dialysis: review of 245 consecutive cases. Clin J Am Soc Nephrol 2007; 2:245.</a></li><li><a class="nounderline abstract_t">Blake PG. Getting excited about exit sites in peritoneal dialysis? Clin J Am Soc Nephrol 2012; 7:1206.</a></li><li><a class="nounderline abstract_t">Yap DY, Chu WL, Ng F, et al. Risk factors and outcome of contamination in patients on peritoneal dialysis--a single-center experience of 15 years. Perit Dial Int 2012; 32:612.</a></li><li><a class="nounderline abstract_t">Mujais S. Microbiology and outcomes of peritonitis in North America. Kidney Int Suppl 2006; :S55.</a></li><li><a class="nounderline abstract_t">Tzamaloukas AH, Obermiller LE, Gibel LJ, et al. Peritonitis associated with intra-abdominal pathology in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1993; 13 Suppl 2:S335.</a></li><li><a class="nounderline abstract_t">Piraino B. Prevention of peritonitis. Perit Dial Int 1998; 18:244.</a></li><li><a class="nounderline abstract_t">Singharetnam W, Holley JL. Acute treatment of constipation may lead to transmural migration of bacteria resulting in gram-negative, polymicrobial, or fungal peritonitis. Perit Dial Int 1996; 16:423.</a></li><li><a class="nounderline abstract_t">Piraino B. Insights on peritoneal dialysis-related infections. Contrib Nephrol 2009; 163:161.</a></li><li><a class="nounderline abstract_t">Wood CJ, Fleming V, Turnidge J, et al. Campylobacter peritonitis in continuous ambulatory peritoneal dialysis: report of eight cases and a review of the literature. Am J Kidney Dis 1992; 19:257.</a></li><li><a class="nounderline abstract_t">Su CY, Pei J, Lu XH, et al. Gastrointestinal symptoms predict peritonitis rates in CAPD patients. Clin Nephrol 2012; 77:267.</a></li><li><a class="nounderline abstract_t">Holley JL, Bernardini J, Piraino B. Continuous cycling peritoneal dialysis is associated with lower rates of catheter infections than continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1990; 16:133.</a></li><li><a class="nounderline abstract_t">Rodríguez-Carmona A, Pérez Fontán M, García Falcón T, et al. A comparative analysis on the incidence of peritonitis and exit-site infection in CAPD and automated peritoneal dialysis. Perit Dial Int 1999; 19:253.</a></li><li><a class="nounderline abstract_t">Locatelli AJ, Marcos GM, Gómez MG, et al. Comparing peritonitis in continuous ambulatory peritoneal dialysis patients versus automated peritoneal dialysis patients. Adv Perit Dial 1999; 15:193.</a></li><li><a class="nounderline abstract_t">Huang JW, Hung KY, Yen CJ, et al. Comparison of infectious complications in peritoneal dialysis patients using either a twin-bag system or automated peritoneal dialysis. Nephrol Dial Transplant 2001; 16:604.</a></li><li><a class="nounderline abstract_t">Kavanagh D, Prescott GJ, Mactier RA. Peritoneal dialysis-associated peritonitis in Scotland (1999-2002). Nephrol Dial Transplant 2004; 19:2584.</a></li><li><a class="nounderline abstract_t">Bender FH, Bernardini J, Piraino B. Prevention of infectious complications in peritoneal dialysis: best demonstrated practices. Kidney Int Suppl 2006; :S44.</a></li><li><a class="nounderline abstract_t">Bieber SD, Burkart J, Golper TA, et al. Comparative outcomes between continuous ambulatory and automated peritoneal dialysis: a narrative review. Am J Kidney Dis 2014; 63:1027.</a></li><li><a class="nounderline abstract_t">Johnson DW, Brown FG, Clarke M, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012; 23:1097.</a></li><li><a class="nounderline abstract_t">Montenegro J, Saracho R, Gallardo I, et al. Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrol Dial Transplant 2007; 22:1703.</a></li><li><a class="nounderline abstract_t">Furkert J, Zeier M, Schwenger V. Effects of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates. Perit Dial Int 2008; 28:637.</a></li><li><a class="nounderline abstract_t">Lee HY, Choi HY, Park HC, et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006; 21:2893.</a></li><li><a class="nounderline abstract_t">Srivastava S, Hildebrand S, Fan SL. Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival. Kidney Int 2011; 80:986.</a></li><li><a class="nounderline abstract_t">Szeto CC, Chow KM, Lam CW, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22:552.</a></li><li><a class="nounderline abstract_t">Chuang YW, Shu KH, Yu TM, et al. Hypokalaemia: an independent risk factor of Enterobacteriaceae peritonitis in CAPD patients. Nephrol Dial Transplant 2009; 24:1603.</a></li><li><a class="nounderline abstract_t">Liu D, Lin Y, Gong N, et al. Degree and duration of hypokalemia associated with peritonitis in patients undergoing peritoneal dialysis. Int J Clin Pract 2021; 75:e14188.</a></li><li><a class="nounderline abstract_t">Davies SJ, Zhao J, Morgenstern H, et al. Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysis-International Results from PDOPPS. Kidney Int Rep 2021; 6:313.</a></li><li><a class="nounderline abstract_t">Pichitporn W, Kanjanabuch T, Phannajit J, et al. Efficacy of Potassium Supplementation in Hypokalemic Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial. Am J Kidney Dis 2022; 80:580.</a></li><li><a class="nounderline abstract_t">Pérez-Fontan M, Machado Lopes D, García Enríquez A, et al. Inhibition of Gastric Acid Secretion by H2 Receptor Antagonists Associates a Definite Risk of Enteric Peritonitis and Infectious Mortality in Patients Treated with Peritoneal Dialysis. PLoS One 2016; 11:e0148806.</a></li><li><a class="nounderline abstract_t">Maeda S, Yamaguchi M, Maeda K, et al. Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients. PLoS One 2019; 14:e0224859.</a></li><li><a class="nounderline abstract_t">Nessim SJ, Tomlinson G, Bargman JM, Jassal SV. Gastric acid suppression and the risk of enteric peritonitis in peritoneal dialysis patients. Perit Dial Int 2008; 28:246.</a></li><li><a class="nounderline abstract_t">Zhong HJ, Lin D, Lu ZY, et al. Use of gastric-acid suppressants may be a risk factor for enteric peritonitis in patients undergoing peritoneal dialysis: A meta-analysis. J Clin Pharm Ther 2019; 44:209.</a></li><li><a class="nounderline abstract_t">Boudville N, Kemp A, Clayton P, et al. Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. J Am Soc Nephrol 2012; 23:1398.</a></li><li><a class="nounderline abstract_t">Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25:107.</a></li><li><a class="nounderline abstract_t">Mactier R. Peritonitis is still the achilles' heel of peritoneal dialysis. Perit Dial Int 2009; 29:262.</a></li><li><a class="nounderline abstract_t">Figueiredo AE, Bernardini J, Bowes E, et al. A Syllabus for Teaching Peritoneal Dialysis to Patients and Caregivers. Perit Dial Int 2016; 36:592.</a></li><li><a class="nounderline abstract_t">Hall G, Bogan A, Dreis S, et al. New directions in peritoneal dialysis patient training. Nephrol Nurs J 2004; 31:149.</a></li><li><a class="nounderline abstract_t">Chow KM, Szeto CC, Law MC, et al. Influence of peritoneal dialysis training nurses' experience on peritonitis rates. Clin J Am Soc Nephrol 2007; 2:647.</a></li><li><a class="nounderline abstract_t">Russo R, Manili L, Tiraboschi G, et al. Patient re-training in peritoneal dialysis: why and when it is needed. Kidney Int Suppl 2006; :S127.</a></li><li><a class="nounderline abstract_t">Lalancette C, Charron D, Laferrière C, et al. Hospital Drains as Reservoirs of Pseudomonas aeruginosa: Multiple-Locus Variable-Number of Tandem Repeats Analysis Genotypes Recovered from Faucets, Sink Surfaces and Patients. Pathogens 2017; 6.</a></li><li><a class="nounderline abstract_t">Burkart JM, Jordan JR, Durnell TA, Case LD. Comparison of exit-site infections in disconnect versus nondisconnect systems for peritoneal dialysis. Perit Dial Int 1992; 12:317.</a></li><li><a class="nounderline abstract_t">Burkart JM, Hylander B, Durnell-Figel T, Roberts D. Comparison of peritonitis rates during long-term use of standard spike versus Ultraset in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1990; 10:41.</a></li><li><a class="nounderline abstract_t">Maiorca R, Cantaluppi A, Cancarini GC, et al. Prospective controlled trial of a Y-connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis. Lancet 1983; 2:642.</a></li><li><a class="nounderline abstract_t">Scalamogna A, De Vecchi A, Castelnovo C, et al. Long-term incidence of peritonitis in CAPD patients treated by the Y set technique: experience in a single center. Nephron 1990; 55:24.</a></li><li><a class="nounderline abstract_t">Port FK, Held PJ, Nolph KD, et al. Risk of peritonitis and technique failure by CAPD connection technique: a national study. Kidney Int 1992; 42:967.</a></li><li><a class="nounderline abstract_t">Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multi-centre randomized clinical trial comparing the Y connector disinfectant system to standard systems. Canadian CAPD Clinical Trials Group. Perit Dial Int 1989; 9:159.</a></li><li><a class="nounderline abstract_t">Daly CD, Campbell MK, MacLeod AM, et al. Do the Y-set and double-bag systems reduce the incidence of CAPD peritonitis? A systematic review of randomized controlled trials. Nephrol Dial Transplant 2001; 16:341.</a></li><li><a class="nounderline abstract_t">Dombros N, Dratwa M, Feriani M, et al. European best practice guidelines for peritoneal dialysis. 2 The initiation of dialysis. Nephrol Dial Transplant 2005; 20 Suppl 9:ix3.</a></li><li><a class="nounderline abstract_t">Li PK, Szeto CC, Law MC, et al. Comparison of double-bag and Y-set disconnect systems in continuous ambulatory peritoneal dialysis: a randomized prospective multicenter study. Am J Kidney Dis 1999; 33:535.</a></li><li><a class="nounderline abstract_t">Harris DC, Yuill EJ, Byth K, et al. Twin- versus single-bag disconnect systems: infection rates and cost of continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1996; 7:2392.</a></li><li><a class="nounderline abstract_t">Kiernan L, Kliger A, Gorban-Brennan N, et al. Comparison of continuous ambulatory peritoneal dialysis-related infections with different "Y-tubing" exchange systems. J Am Soc Nephrol 1995; 5:1835.</a></li><li><a class="nounderline abstract_t">Balteau PR, Peluso FP, Coles GA, et al. Design and testing of the Baxter Integrated Disconnect Systems (IDS). Perit Dial Int 1991; 11:131.</a></li><li><a class="nounderline abstract_t">Monteón F, Correa-Rotter R, Paniagua R, et al. Prevention of peritonitis with disconnect systems in CAPD: a randomized controlled trial. The Mexican Nephrology Collaborative Study Group. Kidney Int 1998; 54:2123.</a></li><li class="breakAll">Honkanen E, Kala AR, Gronhagen-Riska C. Divergent etiologies of CAPD peritonitis in integrated double bag and traditional systems?. In: Advances in Continuous Ambulatory Peritoneal Dialysis, 7th ed., Khanna R, Nolph KD, Prowant BF, et al (Eds), University of Toronto Press, Toronto 1991. p.129.</li><li><a class="nounderline abstract_t">Wong HS, Ong LM, Lim TO, et al. A randomized, multicenter, open-label trial to determine peritonitis rate, product defect, and technique survival between ANDY-Disc and UltraBag in patients on CAPD. Am J Kidney Dis 2006; 48:464.</a></li><li><a class="nounderline abstract_t">Chaudhry RI, Chopra T, Fissell R, Golper TA. Strategies to Prevent Peritonitis after Procedures: Our Opinions. Perit Dial Int 2019; 39:315.</a></li><li><a class="nounderline abstract_t">Suzuki Y, Mizuno M, Kojima H, et al. Oral Antibiotics are Effective for Preventing Colonoscopy-associated Peritonitis as a Preemptive Therapy in Patients on Peritoneal Dialysis. Intern Med 2021; 60:353.</a></li><li><a class="nounderline abstract_t">Fan PY, Chan MJ, Lin SH, et al. Prophylactic Antibiotic Reduces the Risk of Peritonitis after Invasive Gynecologic Procedures. Perit Dial Int 2019; 39:356.</a></li><li><a class="nounderline abstract_t">Shukla A, Abreu Z, Bargman JM. Streptococcal PD peritonitis--a 10-year review of one centre's experience. Nephrol Dial Transplant 2006; 21:3545.</a></li><li><a class="nounderline abstract_t">Holley JL, Bernardini J, Piraino B. Characteristics and outcome of peritoneal dialysate leaks and associated infections. Adv Perit Dial 1993; 9:240.</a></li><li><a class="nounderline abstract_t">van Diepen AT, Jassal SV. A qualitative systematic review of the literature supporting a causal relationship between exit-site infection and subsequent peritonitis in patients with end-stage renal disease treated with peritoneal dialysis. Perit Dial Int 2013; 33:604.</a></li></ol></div><div id="topicVersionRevision">Topic 1867 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12027134" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Peritonitis in peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14703200" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Influence of climate on the incidence of peritoneal dialysis-related peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466279" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Catheter-related interventions to prevent peritonitis in peritoneal dialysis: a systematic review of randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2073094" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Testing the susceptibility of bacteria in biofilms to antibacterial agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2073094" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Testing the susceptibility of bacteria in biofilms to antibacterial agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Relationship of adherent bacterial biofilms to peritonitis in chronic ambulatory peritoneal dialysis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Biofilm on the Tenckhoff catheter: A negligible source of contamination</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1768500" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Biofilm formation on peritoneal catheters does not require the presence of infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399599" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Biofilm and peritonitis in peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12046042" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8017479" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Influence of dextrose dialysis solutions on adhesion of Staphylococcus aureus and Pseudomonas aeruginosa to three catheter surfaces.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19776049" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Intraperitoneal urokinase and oral rifampicin for persisting asymptomatic dialysate infection following acute coagulase-negative staphylococcus peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15931649" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8555323" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8555327" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Biocompatibility in peritoneal dialysis: definitions and mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15685516" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A comparison of peritonitis rates from the United States Renal Data System database: CAPD versus continuous cycling peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20829519" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparison of outcomes on continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis: results from a USA database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21804138" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Peritoneal dialysis-associated peritonitis rates and outcomes in a national cohort are not improving in the post-millennium (2000-2007).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22134627" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A randomized controlled trial comparing mupirocin and polysporin triple ointments in peritoneal dialysis patients: the MP3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24927898" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : First-year outcomes of incident peritoneal dialysis patients in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880990" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : ISPD position statement on reducing the risks of peritoneal dialysis-related infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35264029" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17704448" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risks and outcomes of peritonitis after flexible colonoscopy in CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20919445" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : CAPD peritonitis after colonoscopy: follow the guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16686285" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Streptococcus viridans-associated peritonitis after gastroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24751170" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17179509" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Impact of nutritional status on peritonitis in CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612991" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Albumin at the start of peritoneal dialysis predicts the development of peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12900818" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Depression and its association with peritonitis in long-term peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23936514" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prophylactic antibiotics for endoscopy-associated peritonitis in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8465827" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Posthysteroscopy fungal peritonitis in a patient on continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10898055" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Iatrogenic peritonitis: the need for prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37165633" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical characteristics and outcomes of peritoneal dialysis (PD)-related peritonitis after colonoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14274982" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : NASAL RESERVOIR AS THE SOURCE OF EXTRANASAL STAPHYLOCOCCI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2300122" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16757626" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Staphylococcus aureus carriage patterns and the risk of infections associated with continuous peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7999818" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Staphylococcus aureus CAPD-related infections are associated with nasal carriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8804241" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Peritonitis associated with exit site and tunnel infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22745277" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699420" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Staphylococcus aureus peritonitis complicates peritoneal dialysis: review of 245 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22822015" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Getting excited about exit sites in peritoneal dialysis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22661672" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Risk factors and outcome of contamination in patients on peritoneal dialysis--a single-center experience of 15 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17080112" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Microbiology and outcomes of peritonitis in North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399603" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Peritonitis associated with intra-abdominal pathology in continuous ambulatory peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9663885" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prevention of peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8863339" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Acute treatment of constipation may lead to transmural migration of bacteria resulting in gram-negative, polymicrobial, or fungal peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19494610" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Insights on peritoneal dialysis-related infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1553971" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Campylobacter peritonitis in continuous ambulatory peritoneal dialysis: report of eight cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22445469" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Gastrointestinal symptoms predict peritonitis rates in CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2382649" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Continuous cycling peritoneal dialysis is associated with lower rates of catheter infections than continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10433162" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A comparative analysis on the incidence of peritonitis and exit-site infection in CAPD and automated peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10682100" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparing peritonitis in continuous ambulatory peritoneal dialysis patients versus automated peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11239039" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparison of infectious complications in peritoneal dialysis patients using either a twin-bag system or automated peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304559" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Peritoneal dialysis-associated peritonitis in Scotland (1999-2002).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17080111" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prevention of infectious complications in peritoneal dialysis: best demonstrated practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24423779" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparative outcomes between continuous ambulatory and automated peritoneal dialysis: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22440906" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17405794" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981395" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effects of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16957012" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21814174" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005526" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19103738" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hypokalaemia: an independent risk factor of Enterobacteriaceae peritonitis in CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33783932" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Degree and duration of hypokalemia associated with peritonitis in patients undergoing peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33615056" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysis-International Results from PDOPPS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35597332" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Efficacy of Potassium Supplementation in Hypokalemic Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26872254" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Inhibition of Gastric Acid Secretion by H2 Receptor Antagonists Associates a Definite Risk of Enteric Peritonitis and Infectious Mortality in Patients Treated with Peritoneal Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31697753" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18474916" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Gastric acid suppression and the risk of enteric peritonitis in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30332507" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Use of gastric-acid suppressants may be a risk factor for enteric peritonitis in patients undergoing peritoneal dialysis: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22626818" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Recent peritonitis associates with mortality among patients treated with peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15796137" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Peritoneal dialysis-related infections recommendations: 2005 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19458293" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Peritonitis is still the achilles' heel of peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26917664" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A Syllabus for Teaching Peritoneal Dialysis to Patients and Caregivers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114797" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : New directions in peritoneal dialysis patient training.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699477" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Influence of peritoneal dialysis training nurses' experience on peritonitis rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17080104" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Patient re-training in peritoneal dialysis: why and when it is needed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28792484" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Hospital Drains as Reservoirs of Pseudomonas aeruginosa: Multiple-Locus Variable-Number of Tandem Repeats Analysis Genotypes Recovered from Faucets, Sink Surfaces and Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1511049" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Comparison of exit-site infections in disconnect versus nondisconnect systems for peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2085581" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Comparison of peritonitis rates during long-term use of standard spike versus Ultraset in continuous ambulatory peritoneal dialysis (CAPD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6136794" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Prospective controlled trial of a Y-connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2191231" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Long-term incidence of peritonitis in CAPD patients treated by the Y set technique: experience in a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1453589" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Risk of peritonitis and technique failure by CAPD connection technique: a national study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2488361" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multi-centre randomized clinical trial comparing the Y connector disinfectant system to standard systems. Canadian CAPD Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158410" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Do the Y-set and double-bag systems reduce the incidence of CAPD peritonitis? A systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263750" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : European best practice guidelines for peritoneal dialysis. 2 The initiation of dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10070918" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Comparison of double-bag and Y-set disconnect systems in continuous ambulatory peritoneal dialysis: a randomized prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8959630" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Twin- versus single-bag disconnect systems: infection rates and cost of continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7787152" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Comparison of continuous ambulatory peritoneal dialysis-related infections with different "Y-tubing" exchange systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1854869" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Design and testing of the Baxter Integrated Disconnect Systems (IDS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9853278" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Prevention of peritonitis with disconnect systems in CAPD: a randomized controlled trial. The Mexican Nephrology Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9853278" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Prevention of peritonitis with disconnect systems in CAPD: a randomized controlled trial. The Mexican Nephrology Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16931220" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A randomized, multicenter, open-label trial to determine peritonitis rate, product defect, and technique survival between ANDY-Disc and UltraBag in patients on CAPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31296777" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Strategies to Prevent Peritonitis after Procedures: Our Opinions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33518609" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Oral Antibiotics are Effective for Preventing Colonoscopy-associated Peritonitis as a Preemptive Therapy in Patients on Peritoneal Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31028109" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Prophylactic Antibiotic Reduces the Risk of Peritonitis after Invasive Gynecologic Procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005523" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Streptococcal PD peritonitis--a 10-year review of one centre's experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8105934" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Characteristics and outcome of peritoneal dialysate leaks and associated infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24335122" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : A qualitative systematic review of the literature supporting a causal relationship between exit-site infection and subsequent peritonitis in patients with end-stage renal disease treated with peritoneal dialysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
